A long-term study of istradefylline safety and efficacy in patients with parkinson disease

Clinical Neuropharmacology

Volumn 38, Issue 2, 2015, Pages 41-46

  Kondo, Tomoyoshi ^a   Mizuno, Yoshikuni ^b  

^a Rehabilitation Hananoie Hospital   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

adenosine A2A antagonist; istradefylline; long term; Parkinson disease; safety

Indexed keywords

ISTRADEFYLLINE; LEVODOPA; PLACEBO; ADENOSINE A2 RECEPTOR ANTAGONIST; PURINE DERIVATIVE;

AGED; ARTICLE; CONTROLLED STUDY; CONTUSION; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HUMAN; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOMNOLENCE; VISUAL HALLUCINATION; WEIGHT REDUCTION; CLINICAL TRIAL; DOSE RESPONSE; LONGITUDINAL STUDY; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADENOSINE A2 RECEPTOR ANTAGONISTS; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; PURINES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925871478     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000073     Document Type: Article

References (18)

1. Rajput AH, Fenton ME, Birdi S, et al. Clinical-pathological study of levodopa complications. Mov Disord 2002;17(2):289-296
2. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(11 Suppl 5):S1-S88
3. Obeso JA, Rodriguez MC, De Long MR. Basal ganglia pathophysiology. A critical review. Adv Neurol 1997;74:3-18
4. Gatev P, Darbin O, Wichmann T. Oscillations in the basal ganglia under normal conditions and in movement disorders. Mov Disord 2006; 21(10):1566-1577
5. Popoli P, Blum D, Pintor A. The controversial role of adenosine A2A receptor antagonists as neuroprotective agents. Curr Med Chem CNS Agents 2004;4:35-45
6. Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin Investig Drugs 2005; 14(6):729-738
7. Mori A, Shindou T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology 2003; 61(11 Suppl 6):S44-S48
8. Kase H, Aoyama S, Ichimura M, et al. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology 2003;61(11 Suppl 6):S97-S100
9. Hauser RA, Hubble JP, Truong DD, et al. Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology 2003;61(3):297-303
10. Park A, Stacy M. Istradefylline for the treatment of Parkinson's disease. Expert Opin Pharmacother 2012;13(1):111-114
11. Mizuno Y, Hasegawa K, Kondo T, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord 2010;25(10):1437-1443
12. Mizuno Y, Kondo TJapanese Istradefylline Study Group. Adenosine A2A receptor antagonist istradefylline reduces daily off time in Parkinson's disease. Mov Disord 2013;28(8):1138-1141
13. Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: further validation and implications for clinical trials. Mov Disord 2004;19(12): 1409-1413
14. LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces off time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008;63(3):295-302
15. Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008;70 (23):2233-2240
16. Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008;23(15):2177-2185
17. Pourcher E, Fernandez HH, Stacy M, et al. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord 2012;18(2):178-184
18. Factor S, Mark MH, Watts R, et al. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism Relat Disord 2010;16:423-426